Please login to the form below

Not currently logged in
Email:
Password:

Alzheimer's disease

This page shows the latest Alzheimer's disease news and features for those working in and with pharma, biotech and healthcare.

US ‘unicorn’ Samumed on track with lead arthritis drug

US ‘unicorn’ Samumed on track with lead arthritis drug

Samumed will showcase another of its pipeline drugs this week at the Clinical Trials on Alzheimer’s Disease (CTAD) Congress, which started in Barcelona yesterday. ... Preclinical data on DYRK1A inhibitor SM07883, which the company says is a potential

Latest news

More from news
Approximately 47 fully matching, plus 295 partially matching documents found.

Latest Intelligence

  • Key considerations for disease- modifying Parkinson’s disease trials Key considerations for disease- modifying Parkinson’s disease trials

    Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s.The anti-Parkinson medications available primarily promote dopamine levels in the brain to compensate for the loss of ... The design of such neuroprotective

  • Deal Watch January 2018

    Under this transaction Takeda gains options to three Denali programmes for neurodegenerative disorders: the ATV: BACE1/Tau and ATV: TREM2 programmes, which are both at preclinical stage for Alzheimer's disease, ... Option exercise (2 options). 640.

  • Pfizer and IBM's tech-enabled 'Parkinson’s house' Pfizer and IBM's tech-enabled 'Parkinson’s house'

    But this elegant home, surrounded by manicured lawns, is wired to beat the scourge of Parkinson’s disease. ... Since this article was written Pfizer has substantially scaled back its neuroscience R&D work into conditions such as Parkinson's and

  • Holding on to hope for Alzheimer’s advances Holding on to hope for Alzheimers advances

    All we really know is that evidence of amyloid deposition begins up to maybe 20 years before the onset of Alzheimer’s disease. ... Of course, the possibility remains that neither tau nor amyloid are responsible for the development of Alzheimer’s

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    The in-partnering deals included the $1bn deal with Bicycle Therapeutics and the Alzheimer's collaboration with Lilly. ... development agreement with AstraZeneca for a phase I antibody selective for amyloid-beta 42 in Alzheimer's disease.

More from intelligence
Approximately 1 fully matching, plus 25 partially matching documents found.

Latest appointments

  • J&J’s clinical research neuroscience director joins MedAvante J&J’s clinical research neuroscience director joins MedAvante

    Prior to this, he was medical director, global medical affairs for Janssen's Alzheimer's disease immunotherapy unit from June 2011 to May 2013. ... He also brings extensive experience in psychiatry, neurology and dermatology, making him an ideal addition

  • Asceneuron appoints chief medical officer Asceneuron appoints chief medical officer

    Alzheimer's disease. ... His outstanding track record and expertise in neurodegenerative disease are crucial as we are about to progress our first highly brain penetrant and orally bioavailable tau modifier into the clinic for

  • Pfizer appoints chief scientific officer Pfizer appoints chief scientific officer

    Having first joined Harvard in 1989, Dr Isacson's work in neurogenerative disorders, particularly for Parkinson's disease, has become internationally renowned with his laboratory now one of the leading academic ... s disease, where we are working to

  • Chase adds former Allergan execs to leadership team Chase adds former Allergan execs to leadership team

    With its robust intellectual property, pharmaceutical assets and elegant development strategy, Chase has the opportunity to profoundly reshape the approach to the symptomatic treatment of Alzheimer's disease. ... disease.”. 20th June 2016.

  • Eisai recruits Pfizer and Sanofi execs to neurology group Eisai recruits Pfizer and Sanofi execs to neurology group

    Eisai has also appointed Beyhan Zaim to its US Neurology Business Group as VP, commercial development and Alzheimer's Disease global lead. ... As global lead for Alzheimer's Disease she will also be tasked with developing strategies and heading internal

More from appointments
Approximately 0 fully matching, plus 18 partially matching documents found.

Latest from PMHub

  • The dark side of direct-to-consumer genetic tests

    Instead,   they interpret single-nucleotide polymorphisms (SNPs), and while SNPs can indicate a gene is associated with a disease, many are benign and have no impact on health. ... Who can blame them? If an email landed in your inbox that appeared to

  • Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies

    the US suffer from Alzheimer’s disease, and  795, 000  Americans suffer from strokes annually. ... It’s a little bit like it was in the old days of buying IBM computers,” he says.

  • Synergy Vision

    Alzheimer's and Brain Awareness Month. ... June 2017 is Alzheimer’s and Brain Awareness Month, which aims to raise awareness about Alzheimer’s disease (AD) and other types of dementia.

  • Alzheimer's and Brain Awareness Month

    June 2017 is Alzheimer’s and Brain Awareness Month, which aims to raise awareness about Alzheimer’s disease (AD) and other types of dementia. ... June 2017 is Alzheimer’s and Brain Awareness Month, which aims to raise awareness about Alzheimer’s

  • Atlantis Healthcare

    We have delivered over 130 international support programmes across 90+ disease states including, among others: Alzheimer’s disease. ... It’s enlightening to see such an innovative support programme aimed at tackling some of the fundamental issues in

More from PMHub
Approximately 2 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics